AM Best Affirms Credit Ratings of Factory Mutual Insurance Company and Its Subsidiaries
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term... Read more.
AM Best Affirms Credit Ratings of Factory Mutual Insurance Company and Its Subsidiaries
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term... Read more.
Pharmaceutical Collaboration Deals Insight: New Report Analyzes Strategic Alliances from 2019-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Collaboration Deals in Pharmaceuticals 2019-2023” report has been added to ResearchAndMarkets.com’s offering.... Read more.
Pharmaceuticals and Biotechnology Co-Development Deal Trends Explored for 2016-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2023” report has been added to ResearchAndMarkets.com’s... Read more.
CTL Partners With Orange EV on DOT Electric Yard Trucks
Leading to a Safer and Cleaner Future ROSELAND, N.J.–(BUSINESS WIRE)–#EVTransport–Commercial Trailer Leasing, Inc. (CTL) announces a partnership... Read more.
flyExclusive Announces $25 Million Strategic Investment from ETG FE, LLC
Investment Proceeds to Accelerate Fractional Program Growth KINSTON, N.C.–(BUSINESS WIRE)–flyExclusive (NYSEAMERICAN: FLYX) (“flyExclusive” or the... Read more.
United Kingdom Wills, Probate & Trusts Market Report 2023: Steady Year-on-Year Growth Ahead and More Digitisation On The Way – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “UK Wills, Probate & Trusts Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.... Read more.
Principal® Charity Classic renews investment in the Legacy Project
New curriculum incorporated into the community-driven, work-based learning program DES MOINES, Iowa–(BUSINESS WIRE)–The Principal® Charity Classic with... Read more.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients AMBASSADOR (A031501)/KEYNOTE-123 is the first... Read more.
Cushman & Wakefield Elevates Sustainability Solutions with Measurabl
CHICAGO–(BUSINESS WIRE)–#cre–Cushman & Wakefield (NYSE: CWK), a global leader in real estate services, today announced an innovative and strategic... Read more.